31

MYUNG IN PHARMA CO LTD

317450 · KO · Healthcare / Drug Manufacturers - General

41,800.00KRW-300.00 (-0.71%)

Price History

Full chart

Market Stats

Previous Close42,100.00
Open42,100.00
Day Range41,750.00 – 42,900.00
52-Week Range38,672.21 – 114,948.64
Volume9.08K
Market Cap637.29B
P/E (TTM)0.00
Forward P/E0.00
Dividend Yield4.58%
50-Day Avg44,199.00
200-Day Avg52,679.50

About

Myung In Pharmaceutical LTD., a pharmaceutical company, manufactures ETC and OTC drugs. It offers products in the areas of thrombosis and anti-platelet, anti-hypertensive, anti-angina, anti-parkinson, anti-dementia, anti-epileptics, anti-schizophrenia, anti-depressants, adhd, anti-insomnia, gum disease treatment, gastrointestinal, cold-cough medicine, anti-fever, anti-pain, anti-inflammation agent, nutrition supplements and other pharmaceuticals. The company also provides APIs, such as benztropine mesylate, benidipine hcl, clopidogrel bisulfate, haloperidol, paroxetine hcl, pimozide, quetiapine fumarate, rasagiline mesylate, risperidone, sumatriptan succinate, trazodone hci, triazolam, levetiracetam, carbamazepine, benserazide hydrochloride, escitalopram oxalate, vortioxetine hbr, brivaracetam, edoxban tosylate, opicapone, brexpiprazole, guanfacine hydrochloride, lacosamide, lurasidone hydrochloride. Myung In Pharmaceutical LTD. was founded in 1985 and is based in Hwaseong-si, South Korea.

Company Details

  • SectorHealthcare
  • IndustryDrug Manufacturers - General
  • CEOMr. Hang-Myung Lee
  • Headquarters361-12, Noha-gil, Hwaseong-si, South Korea, Korea
  • Websitehttps://myunginph.co.kr

Leadership

  • Mr. Hang-Myung LeeChairman, CEO & President · b. 1949
  • Mr. Dongcheol LeePresident, Chief Administrative Officer & Director · b. 1959
  • Mr. BongKwon ChaPresident & Chief Sales Officer · b. 1963
  • Mr. Haesuk OhMD, Head of Finance Division Director · b. 1967
  • Mr. Hohyeong ChoiMD & Quality Control Manage of Plant 1 · b. 1970
  • Ms. Hyesook NaMD & Quality Control Manager of Plant 2 · b. 1967
  • Mr. Hyunkyu KimMD & Director of the Synthetic Research Lab of Plant 2 · b. 1969
  • Mr. JaeHyung MoMD & Director of Sales Management · b. 1969
  • Mr. JungWook LeeMD and Head of Research & Development Division · b. 1974
  • Mr. SeonBok YoonMD & Director of General Hospital · b. 1966

Financials

Income Statement

Currency: KRW2021-12-312022-12-312025-12-31
Total Revenue209.25B-287.25B
Cost of Revenue70.95B-113.27B
Gross Profit--173.99B
Gross Margin--60.57%
Operating Expense--81.49B
Operating Income--92.50B
Operating Margin--32.20%
EBITDA--113.30B
EBITDA Margin--39.44%
Net Income-57.43B81.44B
Net Income Margin--28.35%
R&D--5.15B
R&D as % of Total Revenue--1.79%
Interest Expense--235.34M
Interest Expense % of Total Revenue--0.08%

Balance Sheet

Currency: KRW2021-12-312023-12-312024-12-312025-12-31
Total Assets---841.67B
Total Liabilities53.67B--47.30B
Total Equity376.09B--794.38B
Cash52.97B--31.79B

Cash Flow

Currency: KRW2021-12-312022-12-312024-12-312025-12-31
Operating Cash Flow-61.04B-81.56B
Capital Expenditure00034.85B
Free Cash Flow-57.64B-46.71B
Dividends Paid---11.20B
FCF to OCF-94.43%-57.27%
Dividend Paid to FCF---23.98%

Earnings

Report DateDec 31, 2025Mar 31, 2026Jun 30, 2026
EPS Estimate---
EPS Actual1592.661556.911665.91
Surprise---
Timing---

Key Statistics & Ratios

Market Cap637.29B
Enterprise Value144.18B
Trailing P/E0.00
Forward P/E0.00
Price / Sales2.17
Price / Book0.75
Revenue (TTM)293.03B
Gross Profit (TTM)181.00B
EBITDA108.47B
Profit Margin30.32%
Operating Margin36.28%
Return on Equity12.91%
Return on Assets8.31%
Shares Outstanding14.60M
Shares Float2.51M
Dividend Yield4.58%
Dividend Rate2,000.00
Payout Ratio41.53%

Dividends

20261×
500.00Aug 28, 2026
20251×
1500.00Dec 29, 2025